Skip to main content
. 2022 May 21;1(5):720–732. doi: 10.1016/j.gastha.2022.05.004

Table 2.

Novel Targeted Therapies for EoE

Drug Target MOA Reference
Omalizumab IgE Lowers free IgE levels Clayton 201450
Mepolizumab IL-5 Stops IL-5 from binding to its receptor on the surface of eosinophils and decreases eosinophil accumulation Straumann 201092; Assa’ad 201193; Otani 201395
Reslizumab IL-5 Blocks IL-5 signaling on eosinophils and eosinophil accumulation Spergel 201294; Markowitz 2018127
Benralizumab IL-5 receptor alpha Blocks IL-5 signaling; induces eosinophil apoptosis via NK cell–mediated antibody-dependent cellular cytotoxicity Bleecker 2016128; Kolbeck 2010129
Cendakimab (RPC4046) IL-13 Binds to the IL-13 ligand, inhibits binding to IL-13Rα1 and IL-13Rα2 subunits Hirano 2019130; Dellon 2021119
Dupilumab IL-4 receptor alpha Blocks signaling of IL-4 and IL-13 that contribute to type 2 inflammation in EoE Hirano 202014
Lirentelimab (AK002) Siglec8 Blocks Siglec8 signaling, leading to eosinophil depletion and mast cell inhibition Dellon 2020131
Etrasimod S1P receptor Modulates S1P receptor signaling to block lymphocyte trafficking to sites of inflammation

S1P, sphingosine 1 phosphate; Siglec8, sialic acid–binding Ig-like lectin 8.